Dr. Jing Liu joined RayThera in February 2024 as the Vice President of Technical Operations, leading all CMC and clinical supply chain activities. Jing brings extensive experiences in drug substance and drug product R&D, manufacturing, CMC regulatory filing, and supply chain. Prior to RayThera, Jing was the Vice President, Technical Operations at XinThera before its acquisition by Gilead in May 2023. Prior to XinThera, Jing was the Executive Director of CMC at Turning Point Therapeutics from 2017 to 2022. As the founding member of the CMC department, Jing oversaw the development of lead asset, repotrectinib (now Augtyro® marketed by BMS), from initial development to commercial launch preparation. He also played instrumental roles in the advancement of three additional clinical candidates. Previously Jing held positions of increasing responsibilities at Janssen Pharmaceuticals and Dart Neuroscience and helped to bring multiple compounds from discovery into development. Jing received his B.S. degree in chemistry at Peking University and Ph.D. in organic chemistry at University of Illinois Urbana-Champaign.
.webp)